Year | 2001 | 2005 | 2010 | 2013 | rs* | p value* |
---|---|---|---|---|---|---|
Evaluated HbA1c (NGSP) (n) | 170 | 170 | 170 | 170 | ||
HbA1c (NGSP)a (%) | 8.2 ± 0.9 | 8.0 ± 0.9 | 7.9 ± 1.0 | 7.7 ± 1.1 | −0.22 | <0.01 |
HbA1c (IFCC)a (mmol/mol) | 67 ± 10 | 64 ± 9 | 63 ± 11 | 60 ± 12 | ||
HbA1c (NGSP) groupb | ||||||
<6% (%) | 0 (0.0) | 0 (0.0) | 1 (1) | 1 (1) | ||
≥6% and <7% (%) | 14 (8) | 15 (9) | 21 (12) | 45 (27) | ||
≥7% and <8% (%) | 51 (30) | 73 (43) | 79 (47) | 72 (42) | ||
≥8% (%) | 105 (62) | 82 (48) | 69 (41) | 52 (31) | <0.01# |
Year | 2003 | 2005 | 2010 | 2013 | rs* | p value* |
---|---|---|---|---|---|---|
Evaluated glycated albumin (n) | 136 | 170 | 170 | 168 | ||
Glycated albumina (%) | 23.5 ± 3.6 | 22.8 ± 3.5 | 22.3 ± 3.9 | 21.5 ± 4.4 | −0.14 | <0.01 |
Glycated albumin quartileb | ||||||
<19.7% (%) | 20 (15) | 28 (17) | 45 (27) | 59 (35) | ||
≥19.7% and <22.0% (%) | 27 (20) | 52 (31) | 45 (27) | 47 (28) | ||
≥22.0% and <24.6% (%) | 42 (31) | 40 (24) | 43 (25) | 26 (16) | ||
≥24.6% (%) | 47 (35) | 50 (29) | 37 (22) | 36 (21) | <0.01# |